Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

Abstract: This paper investigates State of Charge (SoC) estimation and Constant Current-Constant Voltage (CC-CV) charging techniques for Lithium-Ion (Li-Ion) batteries for Electric Vehicles (EVs) ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...